NARCAN
NALOXONE HYDROCHLORIDE
Approval overview NARCAN is listed in Drugs@FDA under application 016636 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ADAPT Submission history Latest submission status date: 2002-10-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview NARCAN is listed in Drugs@FDA under application 016636 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ADAPT Submission history Latest submission status date: 2002-10-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.